Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Institut Paoli-Calmettes · Hotel Dieu Hospital · +20 more institutions
Abstract
Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group). The primary end point was progression-free survival.
Citation impact
- FWCI
- 102.67
- Percentile
- 100%
- References
- 32
Authors
26- PMPhilippe MoreauCorresponding
Institut Paoli-Calmettes, Hotel Dieu Hospital
- TMTamás Masszi
Semmelweis University, Institut Paoli-Calmettes, Unified Szent István and Szent László Hospital
- NGNorbert Grząśko
Institut Paoli-Calmettes, Medical University of Lublin
- NJNizar J. Bahlis
Institut Paoli-Calmettes, University of Calgary
- MHMarkus Hansson
Skåne University Hospital, Institut Paoli-Calmettes, Lund University
Topics & keywords
- Lenalidomide
- Ixazomib
- Medicine
- Multiple myeloma
- Dexamethasone
- Oncology
- Internal medicine
- Dermatology
- Good health and well-being